Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $29.00.
KMTS has been the subject of several research reports. Wall Street Zen lowered shares of Kestra Medical Technologies from a "hold" rating to a "sell" rating in a report on Sunday, November 8th. Piper Sandler reiterated an "overweight" rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. BTIG Research reissued a "buy" rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Royal Bank Of Canada set a $30.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They issued an "overweight" rating and a $30.00 target price for the company.
Check Out Our Latest Stock Report on KMTS
Kestra Medical Technologies Stock Performance
Kestra Medical Technologies stock opened at $25.13 on Friday. The company has a market cap of $1.50 billion, a PE ratio of -9.41 and a beta of 0.45. The company has a fifty day moving average price of $27.68 and a two-hundred day moving average price of $24.17. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. Kestra Medical Technologies has a 12 month low of $17.34 and a 12 month high of $31.99.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The business had revenue of $30.97 million for the quarter. Research analysts expect that Kestra Medical Technologies will post -2.45 earnings per share for the current year.
Insider Buying and Selling at Kestra Medical Technologies
In other Kestra Medical Technologies news, insider Traci S. Umberger sold 30,000 shares of the stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $30.03, for a total value of $900,900.00. Following the sale, the insider directly owned 195,825 shares of the company's stock, valued at $5,880,624.75. This trade represents a 13.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Vaseem Mahboob sold 4,788 shares of the firm's stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $30.60, for a total value of $146,512.80. Following the completion of the sale, the chief financial officer owned 60,609 shares in the company, valued at $1,854,635.40. The trade was a 7.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 251,456 shares of company stock worth $7,173,746. Corporate insiders own 5.30% of the company's stock.
Hedge Funds Weigh In On Kestra Medical Technologies
Several institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC boosted its stake in Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company's stock valued at $25,000 after purchasing an additional 784 shares during the period. Global Retirement Partners LLC increased its stake in shares of Kestra Medical Technologies by 56,300.0% in the third quarter. Global Retirement Partners LLC now owns 1,692 shares of the company's stock valued at $48,000 after purchasing an additional 1,689 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Kestra Medical Technologies in the third quarter valued at approximately $353,000. Pathstone Holdings LLC acquired a new stake in shares of Kestra Medical Technologies in the third quarter valued at approximately $356,000. Finally, Quantinno Capital Management LP bought a new stake in shares of Kestra Medical Technologies during the first quarter valued at approximately $431,000.
About Kestra Medical Technologies
(
Get Free Report)
Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company's flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient's heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.